Please assess the completion status of the following clinical trial:

Trial Title: A Trial of PTS Via Intratumoral Injection in Patients With Central Air Way NSCLC Severe Obstruction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female inpatients, aged 18 to 83 years old.~* Patients with central air way non-small cell lung cancer (NSCLC) severe obstruction; definition of severe airway obstruction: ≥1/2 trachea is obstructed by tumor; and/or block ≥2/3 of primary bronchi, right and middle bronchi. And the longest diameter of the lesion \> 0.5 cm.~* Pathologically confirmed lung cancer.~* Patients with tracheal tumor lesions suitable for local intratumoral injection via fibro-bronchoscopy.~* At least one measurable lesion that could be evaluated by imaging examination (bronchoscopy, CT, MRI or X-ray etc.) according to the Response Evaluation Criteria in Solid Tumors.~* Blood platelet count ≥ 100,000/mm3.~* Subjects who were able to understand and comply with the trial protocol and give written consent.~Exclusion Criteria:~* Brain metastases.~* History of cardiovascular diseases, including congestive heart failure \> New York Heart Association (NYHA) Grade II. Patients with unstable angina pectoris (angina pectoris symptoms at rest), recent angina pectoris (occurred in the recent 3 months) or with myocardial infarction in recent 6 months must be excluded.~* Severe infections or dysbolism.~* Poor hepatic functional reserve or severe hepatocirrhosis, with abnormal blood coagulation indicators.~* Poor general conditions or cachexia.~* The target lesion had been treated with radiotherapy within 6 months.~* Pregnant or breast-feeding woman.~* Known hypersensitivity to PTS or related compounds.~* Lung cancer lesions not suitable for local treatment.~* Any other reason deemed reasonable by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 83 Years
- Healthy Volunteers: f

Study Arms:
- Para-Toluenesulfonamide (Type: EXPERIMENTAL): 1. .The dose of PTS injected into multiple points in a single tumor was about 0.1-1.0 mL, and the appropriate specific doses were kept within the tumor without leakage. An appropriate low dose could be given firstly, and the following doses could be adjusted based on the response of patient and the tumor.~2. . In general, the daily dose of PTS injected into a single tumor was no more than 5mL, and the daily dose of PTS was no more than 10mL for each patient.~The injection was provided 2-3 times a week, with 2 weeks as a cycle of treatment. No less than 4 times of PTS treatment were recomended for the first cycle of treatment, and for other cycles of treatment, the number of PTS injections could be adjusted appropriately based on the condition of the patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).